Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.

Khamari R, Trinh A, Gabert PE, Corazao-Rozas P, Riveros-Cruz S, Balayssac S, Malet-Martino M, Dekiouk S, Joncquel Chevalier Curt M, Maboudou P, Garçon G, Ravasi L, Guerreschi P, Mortier L, Quesnel B, Marchetti P, Kluza J.

Cell Death Dis. 2018 Feb 27;9(3):325. doi: 10.1038/s41419-018-0340-4.

2.

Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer.

Marinangeli C, Kluza J, Marchetti P, Buée L, Vingtdeux V.

Methods Mol Biol. 2018;1732:289-305. doi: 10.1007/978-1-4939-7598-3_19.

PMID:
29480483
3.

Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.

Marchetti P, Trinh A, Khamari R, Kluza J.

Biochim Biophys Acta. 2018 Apr;1862(4):999-1005. doi: 10.1016/j.bbagen.2018.01.018. Review.

PMID:
29413908
4.

Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs.

André F, Trinh A, Balayssac S, Maboudou P, Dekiouk S, Malet-Martino M, Quesnel B, Idziorek T, Kluza J, Marchetti P.

Int J Biochem Cell Biol. 2017 Apr;85:166-174. doi: 10.1016/j.biocel.2017.02.011. Epub 2017 Mar 1.

PMID:
28259749
5.

Lactate Inhibits the Pro-Inflammatory Response and Metabolic Reprogramming in Murine Macrophages in a GPR81-Independent Manner.

Errea A, Cayet D, Marchetti P, Tang C, Kluza J, Offermanns S, Sirard JC, Rumbo M.

PLoS One. 2016 Nov 15;11(11):e0163694. doi: 10.1371/journal.pone.0163694. eCollection 2016.

6.

Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.

Corazao-Rozas P, Guerreschi P, André F, Gabert PE, Lancel S, Dekiouk S, Fontaine D, Tardivel M, Savina A, Quesnel B, Mortier L, Marchetti P, Kluza J.

Oncotarget. 2016 Jun 28;7(26):39473-39485. doi: 10.18632/oncotarget.7790.

7.

Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response.

Le Rouzic O, Koné B, Kluza J, Marchetti P, Hennegrave F, Olivier C, Kervoaze G, Vilain E, Mordacq C, Just N, Perez T, Bautin N, Pichavant M, Gosset P.

Respir Res. 2016 Jul 26;17(1):94. doi: 10.1186/s12931-016-0408-6.

8.

GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation.

André F, Corazao-Rozas P, Idziorek T, Quesnel B, Kluza J, Marchetti P.

Biochem Biophys Res Commun. 2016 Sep 16;478(2):513-20. doi: 10.1016/j.bbrc.2016.07.053. Epub 2016 Jul 12.

PMID:
27416758
9.

Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma.

Qassemyar A, Gabert PE, Kluza J, Duquennoy-Martinot V, Mortier L, Marchetti P, Guerreschi P.

Melanoma Res. 2016 Jun;26(3):245-53. doi: 10.1097/CMR.0000000000000249.

PMID:
26983079
10.

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.

Marchetti P, Guerreschi P, Mortier L, Kluza J.

Int J Cell Biol. 2015;2015:283145. doi: 10.1155/2015/283145. Epub 2015 Dec 2. Review.

11.

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.

Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S.

Nat Commun. 2015 Jul 2;6:7629. doi: 10.1038/ncomms8629.

12.

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.

Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S.

Cell Discov. 2015 Oct 27;1:15030. doi: 10.1038/celldisc.2015.30. eCollection 2015.

13.

Metabolic features of melanoma: a gold mine of new therapeutic targets?

Marchetti P, Guerreschi P, Kluza J, Mortier L.

Curr Cancer Drug Targets. 2014;14(4):357-70. Review.

PMID:
24720363
14.

Another facet to the anticancer response to lamellarin D: induction of cellular senescence through inhibition of topoisomerase I and intracellular Ros production.

Ballot C, Martoriati A, Jendoubi M, Buche S, Formstecher P, Mortier L, Kluza J, Marchetti P.

Mar Drugs. 2014 Jan 27;12(2):779-98. doi: 10.3390/md12020779.

15.

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R.

Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6.

16.

Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.

Corazao-Rozas P, Guerreschi P, Jendoubi M, André F, Jonneaux A, Scalbert C, Garçon G, Malet-Martino M, Balayssac S, Rocchi S, Savina A, Formstecher P, Mortier L, Kluza J, Marchetti P.

Oncotarget. 2013 Nov;4(11):1986-98.

17.

Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.

Guerreschi P, Scalbert C, Qassemyar A, Kluza J, Ravasi L, Huglo D, Martinot-Duquennoy V, Formstecher P, Marchetti P, Mortier L.

Melanoma Res. 2013 Oct;23(5):373-80. doi: 10.1097/CMR.0b013e328363ed92.

PMID:
23852164
18.

Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, Corroyer-Dulmont A, Bernaudin M, Malet-Martino M, de Lassalle EM, Maboudou P, Formstecher P, Polakowska R, Mortier L, Marchetti P.

Cancer Res. 2012 Oct 1;72(19):5035-47. doi: 10.1158/0008-5472.CAN-12-0979. Epub 2012 Aug 3.

19.

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.

Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, Wada Y, Giaever G, Nislow C.

PLoS One. 2012;7(1):e29798. doi: 10.1371/journal.pone.0029798. Epub 2012 Jan 11.

20.

Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.

Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P, Bailly C, Marchetti P.

Apoptosis. 2012 Apr;17(4):364-76. doi: 10.1007/s10495-011-0681-2.

PMID:
22127645
21.

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

Kluza J, Jendoubi M, Ballot C, Dammak A, Jonneaux A, Idziorek T, Joha S, Dauphin V, Malet-Martino M, Balayssac S, Maboudou P, Briand G, Formstecher P, Quesnel B, Marchetti P.

PLoS One. 2011;6(7):e21924. doi: 10.1371/journal.pone.0021924. Epub 2011 Jul 18.

22.

Hx, a novel fluorescent, minor groove and sequence specific recognition element: design, synthesis, and DNA binding properties of p-anisylbenzimidazole-imidazole/pyrrole-containing polyamides.

Chavda S, Liu Y, Babu B, Davis R, Sielaff A, Ruprich J, Westrate L, Tronrud C, Ferguson A, Franks A, Tzou S, Adkins C, Rice T, Mackay H, Kluza J, Tahir SA, Lin S, Kiakos K, Bruce CD, Wilson WD, Hartley JA, Lee M.

Biochemistry. 2011 Apr 19;50(15):3127-36. doi: 10.1021/bi102028a. Epub 2011 Mar 25.

PMID:
21388229
23.

Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients.

Moreau C, Gosset P, Kluza J, Brunaud-Danel V, Lassalle P, Marchetti P, Defebvre L, Destée A, Devos D.

Neuroscience. 2011 Jan 13;172:110-7. doi: 10.1016/j.neuroscience.2010.10.040. Epub 2010 Oct 25.

PMID:
20977930
24.

Targeting the ICB2 site of the topoisomerase IIalpha promoter with a formamido-pyrrole-imidazole-pyrrole H-pin polyamide.

Franks A, Tronrud C, Kiakos K, Kluza J, Munde M, Brown T, Mackay H, Wilson WD, Hochhauser D, Hartley JA, Lee M.

Bioorg Med Chem. 2010 Aug 1;18(15):5553-61. doi: 10.1016/j.bmc.2010.06.041. Epub 2010 Jun 17.

PMID:
20615712
25.

A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.

Chavda S, Babu B, Yanow SK, Jardim A, Spithill TW, Kiakos K, Kluza J, Hartley JA, Lee M.

Bioorg Med Chem. 2010 Jul 15;18(14):5016-24. doi: 10.1016/j.bmc.2010.05.078. Epub 2010 Jun 4.

PMID:
20579889
26.

Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D.

Ballot C, Kluza J, Lancel S, Martoriati A, Hassoun SM, Mortier L, Vienne JC, Briand G, Formstecher P, Bailly C, Nevière R, Marchetti P.

Apoptosis. 2010 Jul;15(7):769-81. doi: 10.1007/s10495-010-0471-2.

PMID:
20151196
27.

Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D.

Ballot C, Kluza J, Martoriati A, Nyman U, Formstecher P, Joseph B, Bailly C, Marchetti P.

Mol Cancer Ther. 2009 Dec;8(12):3307-17. doi: 10.1158/1535-7163.MCT-09-0639.

28.

Polyamide curvature and DNA sequence selective recognition: use of 4-aminobenzamide to adjust curvature.

Lajiness J, Sielaff A, Mackay H, Brown T, Kluza J, Nguyen B, Wilson WD, Lee M, Hartley JA.

Med Chem. 2009 May;5(3):216-26.

29.

Effects of the N-terminal acylamido group of imidazole- and pyrrole-containing polyamides on DNA sequence specificity and binding affinity.

Westrate L, Mackay H, Brown T, Nguyen B, Kluza J, Wilson WD, Lee M, Hartley JA.

Biochemistry. 2009 Jun 23;48(24):5679-88. doi: 10.1021/bi900242t.

PMID:
19419200
30.

Sequence specific and high affinity recognition of 5'-ACGCGT-3' by rationally designed pyrrole-imidazole H-pin polyamides: thermodynamic and structural studies.

Mackay H, Brown T, Uthe PB, Westrate L, Sielaff A, Jones J, Lajiness JP, Kluza J, O'Hare C, Nguyen B, Davis Z, Bruce C, Wilson WD, Hartley JA, Lee M.

Bioorg Med Chem. 2008 Oct 15;16(20):9145-53. doi: 10.1016/j.bmc.2008.09.034. Epub 2008 Sep 13.

31.

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78.

Kotecha M, Kluza J, Wells G, O'Hare CC, Forni C, Mantovani R, Howard PW, Morris P, Thurston DE, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2008 May;7(5):1319-28. doi: 10.1158/1535-7163.MCT-07-0475.

32.

Modifying the N-terminus of polyamides: PyImPyIm has improved sequence specificity over f-ImPyIm.

Brown T, Mackay H, Turlington M, Sutterfield A, Smith T, Sielaff A, Westrate L, Bruce C, Kluza J, O'Hare C, Nguyen B, Wilson WD, Hartley JA, Lee M.

Bioorg Med Chem. 2008 May 1;16(9):5266-76. doi: 10.1016/j.bmc.2008.03.008. Epub 2008 Mar 7.

PMID:
18353654
33.

Targeting the inverted CCAAT Box-2 of the topoisomerase IIalpha gene: DNA sequence selective recognition by a polyamide-intercalator as a staggered dimer.

Mackay H, Brown T, Sexton JS, Kotecha M, Nguyen B, Wilson WD, Kluza J, Savic B, O'Hare C, Hochhauser D, Lee M, Hartley JA.

Bioorg Med Chem. 2008 Feb 15;16(4):2093-102. Epub 2007 Oct 22.

PMID:
17977733
34.

Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway.

Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castéra L, Cuevas C, Formstecher P, Joseph B, Kroemer G, Bailly C, Marchetti P.

Oncogene. 2008 Mar 27;27(14):1981-92. Epub 2007 Oct 1.

PMID:
17906690
35.

Synthesis and biophysical evaluation of minor-groove binding C-terminus modified pyrrole and imidazole triamide analogs of distamycin.

Brown T, Taherbhai Z, Sexton J, Sutterfield A, Turlington M, Jones J, Stallings L, Stewart M, Buchmueller K, Mackay H, O'hare C, Kluza J, Nguyen B, Wilson D, Lee M, Hartley JA.

Bioorg Med Chem. 2007 Jan 1;15(1):474-83. Epub 2006 Oct 10.

PMID:
17035029
36.

Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter.

Flores LV, Staples AM, Mackay H, Howard CM, Uthe PB, Sexton JS 3rd, Buchmueller KL, Wilson WD, O'Hare C, Kluza J, Hochhauser D, Hartley JA, Lee M.

Chembiochem. 2006 Nov;7(11):1722-9.

PMID:
16991167
37.

Gel permeation chromatography of dextrans in parenteral solutions: calibration procedure development and method validation.

Karmarkar S, Garber R, Kluza J, Koberda M.

J Pharm Biomed Anal. 2006 Jun 16;41(4):1260-7. Epub 2006 May 2.

PMID:
16650708
38.

Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D.

Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JM, Cuevas C, Marchetti P, Bailly C.

Cancer Res. 2006 Mar 15;66(6):3177-87.

39.

Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide.

Kluza J, Mazinghien R, Irwin H, Hartley JA, Bailly C.

Anticancer Drugs. 2006 Feb;17(2):155-64.

PMID:
16428933
40.

Induction of apoptosis by the plant alkaloid sampangine in human HL-60 leukemia cells is mediated by reactive oxygen species.

Kluza J, Mazinghien R, Degardin K, Lansiaux A, Bailly C.

Eur J Pharmacol. 2005 Nov 21;525(1-3):32-40. Epub 2005 Nov 11.

PMID:
16289142
41.

Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction.

Lancel S, Joulin O, Favory R, Goossens JF, Kluza J, Chopin C, Formstecher P, Marchetti P, Neviere R.

Circulation. 2005 May 24;111(20):2596-604. Epub 2005 May 16.

42.

Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.

Vanhuyse M, Kluza J, Tardy C, Otero G, Cuevas C, Bailly C, Lansiaux A.

Cancer Lett. 2005 Apr 28;221(2):165-75.

PMID:
15808402
43.

DNase I footprinting of small molecule binding sites on DNA.

Bailly C, Kluza J, Martin C, Ellis T, Waring MJ.

Methods Mol Biol. 2005;288:319-42.

PMID:
15333913
44.

Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.

Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C.

Oncogene. 2004 Sep 16;23(42):7018-30.

PMID:
15273722
45.

Synthesis of diphenylcarbazoles as cytotoxic DNA binding agents.

Jacquemard U, Routier S, Tatibouët A, Kluza J, Laine W, Bal C, Bailly C, Mérour JY.

Org Biomol Chem. 2004 May 21;2(10):1476-83. Epub 2004 Apr 19.

PMID:
15136803
47.

Cytotoxicity and DNA binding properties of the plant alkaloid burasaine.

Kluza J, Baldeyrou B, Colson P, Rasoanaivo P, Mambu L, Frappier F, Bailly C.

Eur J Pharm Sci. 2003 Dec;20(4-5):383-91.

PMID:
14659482
48.

Plasma stability of two glycosyl indolocarbazole antitumor agents.

Goossens JF, Kluza J, Vezin H, Kouach M, Briand G, Baldeyrou B, Wattez N, Bailly C.

Biochem Pharmacol. 2003 Jan 1;65(1):25-34.

PMID:
12473375
49.

Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1.

Kluza J, Lansiaux A, Wattez N, Hildebrand MP, Léonce S, Pierré A, Hickman JA, Bailly C.

Biochem Pharmacol. 2002 Apr 15;63(8):1443-52.

PMID:
11996885
50.

Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide.

Facompré M, Wattez N, Kluza J, Lansiaux A, Bailly C.

Mol Cell Biol Res Commun. 2000 Jul;4(1):37-42.

PMID:
11152626

Supplemental Content

Support Center